ROKIT America ^{Filed, US Offering, Nasdaq: RKAM}

The Company is committed to extending human health span and enhancing quality of life in an aging society through its proprietary Reverse Aging Product which is intended to support cellular health and aging-related biological processes at the molecular level, and its artificial intelligence hyper-personalized Organ Regeneration Platform, a proprietary technology developed by our parent company, ROKIT Healthcare, which is intended to provide regenerative medicine solutions in the Americas. Since its founding in 2019, the Company has focused on the research and development of dietary supplements centered around ß-Nicotinamide Mononucleotide. We have launched a range of NMN-based products into global markets, including the United States. Our flagship product line, ROKIT AMERICA NMN, combines NMN with pterostilbene, a naturally occurring antioxidant. Certain of our RAP dietary supplement formulations also include additional ingredients, such as fisetin, which we incorporate based on internal research and development focused on supporting cellular health and aging-related biological processes. These products are regulated as dietary supplements and do not require premarket approval by the US FDA. Our ability to compete depends primarily on brand recognition, product quality, marketing execution, and consumer trust, rather than proprietary exclusivity over individual supplement ingredients.